Skip to main content
ScholarsBetaWeill Cornell Medicine

Publications

56 publications

Clinical research

4 studies

Active

2 studies
  • PI
    Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
    PHASE2; PHASE3 · Celgene Corporation · OPEN TO ACCRUAL (as of 2024)
    Neoplasms
    NCT03435796
  • PI
    Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
    Celgene Corporation · OPEN TO ACCRUAL (as of 2021)
    Multiple Myeloma
    NCT04771078
Completed & closed trials (2)
  • PI
    A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
    PHASE3 · Celgene Corporation · IRB STUDY CLOSURE (as of 2026)
    Multiple Myeloma
    NCT03651128
  • PI
    A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
    PHASE3 · Janssen Research & Development, LLC · CLOSED TO ACCRUAL (as of 2024)
    Multiple Myeloma
    NCT04923893